http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
New Bausch + Lomb Social Media Campaign Highlights What ‘Sights’ Inspire AMD Patients
-
Bausch + Lomb Corporation (BLCO) Announce FDA Approval of ML6710i Photodynamic Laser
-
Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)
-
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22
-
Bausch + Lomb Corporation (BLCO) Acquires AcuFocus
-
Bausch + Lomb Acquires AcuFocus, Inc.
-
Bausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels with OCUSorb™
-
Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference
-
Bausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference
-
Bausch + Lomb Corporation (BLCO) and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology
-
Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology
-
Bausch + Lomb and Glaucoma Research Foundation Announce Launch of Screen, Protect, Cure Campaign In Recognition of Glaucoma Awareness Month
-
Bausch + Lomb Corporation (BLCO) Amends CEO Separation Agreement
-
Bausch + Lomb Amends CEO Separation Agreement
-
Bausch + Lomb Corporation (BLCO) Receives 510(k) Clearance from FDA for Biotrue® Hydration Boost Contact Lens Rehydrating Drops
-
Bausch + Lomb Receives 510(k) Clearance from FDA for Biotrue® Hydration Boost Contact Lens Rehydrating Drops
-
Bausch + Lomb's ONE by ONE and Biotrue® Eye Care Recycling Programs Win Gold for Most Environmentally Friendly Service of the Year from Best in Biz Awards
-
Bausch + Lomb's Biotrue® Hydration Plus Multi-Purpose Solution Receives Product of the Year Award from Business Intelligence Group's 2022 BIG Awards for Business
-
Bausch + Lomb Reports More Than 58 Million Units of Contact Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
-
Bausch + Lomb Announces Participation at the 5th Annual Evercore ISI HealthCONx Conference
-
Bausch + Lomb Announces Third-Quarter 2022 Results
-
Bausch + Lomb #LUMIFYEyeDance Challenge Wins 2022 Public Relations and Marketing Excellence Award for External Campaign of the Year from Business Intelligence Group
-
Bausch + Lomb Introduces Project Watson™ Health Care Products for Dogs
-
Bausch + Lomb Announces Presentation of Scientific Data and Analyses Evaluating Biotrue® Hydration Plus Multi-Purpose Solution at American Academy of Optometry Annual Meeting
-
Bausch + Lomb Will Release Third-Quarter 2022 Financial Results on November 2
-
Bausch + Lomb Introduces Enhanced Ocuvite® Adult 50+ Eye Vitamin Formulation With Vitamin D
-
Bausch + Lomb Will Present Scientific Data and Analyses During World Cornea Congress
-
Bausch + Lomb Will Present New Scientific Data and Analyses During the American Academy of Ophthalmology Annual Meeting
-
Bausch + Lomb Announces Webinar for Eye Care Professionals on New AREDS2 Study Findings
-
First Annual Bausch + Lomb Sponsored Visionary Report Spotlights Nation's 'Blind Spots' on Age-related Macular Degeneration, a Leading Cause of Vision Loss for People 50+
-
Bausch + Lomb and Novaliq Announce U.S. FDA Filing Acceptance for Investigational Treatment NOV03 (Perfluorohexyloctane)
-
Bausch + Lomb Named Exclusive Global Distributor of Alfa Instruments s.r.l. Intraocular Dyes
-
Bausch + Lomb Announces Participation at Upcoming Investor Conferences
-
Bausch + Lomb Announces Second-Quarter 2022 Results
-
Bausch + Lomb Launches the #LUMIFYEyeDance Challenge on TikTok
-
Bausch + Lomb and Sanoculis Announce Strategic Agreements Designed to Address Unmet Needs in Glaucoma
-
Bausch + Lomb Corporation (BLCO) Enrolls First Patient in Technolas TENEO Excimer Laser
-
Bausch + Lomb Enrolls First Patient in LASIK Clinical Trial Evaluating Use of Technolas® TENEO™ Excimer Laser* for Vision Correction Surgery for Hyperopia with Astigmatism
-
Bausch + Lomb Will Release Second-Quarter 2022 Financial Results on August 4
-
Bausch + Lomb Corporation (BLCO) Announces Leadership Changes
-
Bausch + Lomb Provides Leadership Update
-
Bausch + Lomb Corporation (BLCO) and Novaliq Submit NDA for NOV03
-
Bausch + Lomb and Novaliq Announce Submission of New Drug Application for Investigational Treatment NOV03 (Perfluorohexyloctane)
-
Bausch + Lomb Corporation (BLCO) Reports Scientific Data on XIPERE
-
Bausch + Lomb Announces Scientific Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) to be Presented During the American Society of Retina Specialists Annual Scientific Meeting
-
Bausch + Lomb (BLCO) Announces Brett Icahn and Gary Hu Have Been Appointed to its Board of Directors
-
Bausch + Lomb Announces Brett Icahn and Gary Hu Have Been Appointed to its Board of Directors
-
Bausch + Lomb Announces the U.S. Launch of Revive™ Custom Soft Contact Lenses
-
Bausch + Lomb Announces First-Quarter 2022 Results and Provides 2022 Guidance
-
Bausch + Lomb Announces Scientific Data on Latest Biotrue® Products to be Presented at American Optometric Association's Optometry's Meeting

